Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucy Gilbert

Showing results (101-110 of 157) with videos related to

Pageof 16
Sort By:
Journal of Comparative Effectiveness Research|April 1, 2020
Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapyLucy Gilbert, Agnihotram V Ramanakumar, Maria Carolina Festa, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 10, 2007
Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasiaAndrea Schaffer, Anita Koushik, Helen Trottier, et al.
Gynecologic Oncology Reports|December 1, 2025
Use of doxorubicin and trabectedin in low-grade endometrial stromal sarcoma: A case reportDélya Valcourt-Gendron, Basile Tessier-Cloutier, Xing Zeng, et al.
Lancet (London, England)|September 6, 2017
The empress of subterfuge: cancer of the fallopian tube presenting with malapropismLucy Gilbert, Timothée Revil, Charles Meunier, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
Gynecologic Oncology|July 8, 2022
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysisKaren Cadoo, Fiona Simpkins, Cara Mathews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2018
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab SoravtansineUrsula A Matulonis, Michael J Birrer, David M O'Malley, et al.
BMC Public Health|October 2, 2025
Exploring stakeholder perceptions and priorities related to reducing tick-related public health risks in natural environments of the United KingdomFestus A Asaaga, Emmanuel S Tomude, Hermann Kam, et al.
JAMA Oncology|October 1, 2020
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical TrialAna Oaknin, Anna V Tinker, Lucy Gilbert, et al.
Future Oncology (London, England)|August 24, 2021
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancerAna Oaknin, Anna V Tinker, Lucy Gilbert, et al.
Pageof 16

Showing results (101-110 of 157) with videos related to

Sort By:
Pageof 16
Journal of Comparative Effectiveness Research|April 1, 2020
Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapyLucy Gilbert, Agnihotram V Ramanakumar, Maria Carolina Festa, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 10, 2007
Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasiaAndrea Schaffer, Anita Koushik, Helen Trottier, et al.
Gynecologic Oncology Reports|December 1, 2025
Use of doxorubicin and trabectedin in low-grade endometrial stromal sarcoma: A case reportDélya Valcourt-Gendron, Basile Tessier-Cloutier, Xing Zeng, et al.
Lancet (London, England)|September 6, 2017
The empress of subterfuge: cancer of the fallopian tube presenting with malapropismLucy Gilbert, Timothée Revil, Charles Meunier, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
Gynecologic Oncology|July 8, 2022
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysisKaren Cadoo, Fiona Simpkins, Cara Mathews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2018
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab SoravtansineUrsula A Matulonis, Michael J Birrer, David M O'Malley, et al.
BMC Public Health|October 2, 2025
Exploring stakeholder perceptions and priorities related to reducing tick-related public health risks in natural environments of the United KingdomFestus A Asaaga, Emmanuel S Tomude, Hermann Kam, et al.
JAMA Oncology|October 1, 2020
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical TrialAna Oaknin, Anna V Tinker, Lucy Gilbert, et al.
Future Oncology (London, England)|August 24, 2021
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancerAna Oaknin, Anna V Tinker, Lucy Gilbert, et al.
Pageof 16